Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00026611 · ClinicalTrials.gov registry record · Phase 2
A Study of Dryvax Vaccine Against Smallpox in Previously Unvaccinated Adults
A Phase 2 study, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Completed
- Registry status
- Phase 2
- Development phase
NCT00026611 is a Phase 2 study that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID).
The verdict
NCT00026611, a Phase 2 study, has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- COMPLETED
- Registry status
- Phase 2
- Development phase
Study Summary
The purpose of this study is to see how many people respond to a smallpox vaccine when a sore forms where the shot was given. The world was declared free of smallpox in 1980. General routine vaccinations for smallpox were stopped in the U.S. in 1971. In 1976, the recommendation for routine vaccination of healthcare workers was also discontinued. The only people who presently receive this vaccine are people who work with vaccinia virus or monkeypox virus. Because the world was considered free of smallpox infections, this vaccine was no longer produced; there is a limited supply available in the United States. Because of the limited amount of Dryvax vaccine (vaccinia virus) against smallpox, this study will look at the ability to dilute the vaccine making more doses available in the event of a smallpox outbreak. The study seeks to characterize a strategy of vaccination against smallpox with various doses of Dryvax, followed by revaccination with the same dose, if required, in volunteers 18-32 years of age with a negative history of smallpox vaccination.
Interventions
- BIOLOGICAL Dryvax vaccine
Trial Details
| Field | Value |
|---|---|
| Est. Completion | 2001-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00026611
The ClinicalTrials.gov registry entry for NCT00026611 describes a study currently listed as completed, categorized as Phase 2. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Dryvax vaccine is the first listed.
NCT00026611 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00026611 about?
NCT00026611 is a clinical study titled "A Study of Dryvax Vaccine Against Smallpox in Previously Unvaccinated Adults". The purpose of this study is to see how many people respond to a smallpox vaccine when a sore forms where the shot was given. The world was declared free of smallpox in 1980. General routine vaccinations for smallpox were stopped in the U.S. in 1971. In 1976, the recommendation for routine vaccinat...
What is the current status of trial NCT00026611?
This trial is currently completed. It is a Phase 2 study. Estimated completion is 2001-12.
What interventions are being tested in trial NCT00026611?
The interventions under investigation include: Dryvax vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT00026611?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.